Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Warrington, Pennsylvania 18976


Purpose:

Surfaxin treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as BPD, in premature infants who have required continued intubation and received surfactants for the prevention or treatment of Respiratory Distress Syndrome (RDS).


Study summary:

Determine the safety and tolerability of Surfaxin administration in the first weeks of life as a therapeutic approach for prevention of BPD. Determine whether treatment with Surfaxin during the first two to three weeks of life can decrease the proportion of infants on mechanical ventilation or oxygen or the incidence of death or BPD in VLBW infants when assessed at 28 days of life and 36 weeks post-menstrual age (as determined by the need for supplemental oxygen).


Criteria:

Inclusion Criteria: Premature infants between 600 and 900 grams birth weight Exclusion Criteria:


NCT ID:

NCT00215540


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Warrington, Pennsylvania 18976
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.